We prospectively evaluated relapse frequency and quality of life as assessed by the MS-QOL-54 questionnaire in 2 groups of relapsing-remitting MS patients with similar pre-treatment relapse rate and treated either with azathioprine or with beta IFN1b for one year. A marked reduction in relapse frequency occurred in both groups; no significant shifts occurred in the quality of life measurement. The results suggest further randomized studies of azathioprine and IFN beta in the therapy of relapsing-remitting MS.
|Number of pages||3|
|Journal||Rivista di Neurobiologia|
|Publication status||Published - 1999|
ASJC Scopus subject areas